Kinnate Biopharma Inc. – NASDAQ:KNTE
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Kinnate Biopharma stock price monthly change
+16.74%
month
Kinnate Biopharma stock price quarterly change
+4.74%
quarter
Kinnate Biopharma stock price yearly change
-61.26%
year
Kinnate Biopharma key metrics
Market Cap | 124.99M |
Enterprise value | 244.60M |
P/E | -2.36 |
EV/Sales | N/A |
EV/EBITDA | -1.44 |
Price/Sales | N/A |
Price/Book | 1.20 |
PEG ratio | 0.08 |
EPS | -2.38 |
Revenue | N/A |
EBITDA | -120.58M |
Income | -110.93M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKinnate Biopharma stock price history
Kinnate Biopharma stock forecast
Kinnate Biopharma financial statements
| Mar 2023 | 0 | -31.22M | |
|---|---|---|---|
| Jun 2023 | 0 | -31.91M | |
| Sep 2023 | 0 | -30.73M | |
| Dec 2023 | 0 | -17.05M |
| Dec 2023 | 0 | -17.05M | |
|---|---|---|---|
| Sep 2025 | 0 | -8.95M | |
| Dec 2025 | 0 | -13.76M | |
| Dec 2025 | 0 | -8.95M |
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 243880000 | 21.11M | 8.66% |
|---|---|---|---|
| Jun 2023 | 216135000 | 18.51M | 8.57% |
| Sep 2023 | 190709000 | 18.28M | 9.59% |
| Dec 2023 | 173605000 | 14.27M | 8.22% |
| Mar 2023 | -27.72M | 55.42M | -9.11M |
|---|---|---|---|
| Jun 2023 | -29.42M | -10.88M | 1.25M |
| Sep 2023 | -25.53M | 42.63M | 57K |
| Dec 2023 | -17.36M | 13.56M | 9.13M |
Kinnate Biopharma alternative data
| Aug 2023 | 94 |
|---|---|
| Sep 2023 | 84 |
| Oct 2023 | 84 |
| Nov 2023 | 84 |
| Dec 2023 | 84 |
| Jan 2024 | 84 |
| Feb 2024 | 84 |
| Mar 2024 | 84 |
| Apr 2024 | 84 |
| May 2024 | 84 |
| Jun 2024 | 84 |
| Jul 2024 | 84 |
Kinnate Biopharma other data
47.98%
-44.48%
of KNTE is owned by hedge funds
38
-41
21.14M
-19.67M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2023 | 701498 | 0 |
| May 2023 | 8057044 | 0 |
| Patent |
|---|
Grant Filling date: 2 May 2019 Issue date: 20 Sep 2022 |
Grant Utility: Inhibitors of RAF kinases Filling date: 16 Sep 2021 Issue date: 9 Aug 2022 |
Grant Filling date: 11 Nov 2020 Issue date: 19 Jul 2022 |
Grant Utility: Inhibitors of RAF kinases Filling date: 11 Oct 2021 Issue date: 5 Jul 2022 |
Grant Filling date: 4 Jun 2021 Issue date: 31 May 2022 |
Application Filling date: 11 Oct 2021 Issue date: 14 Apr 2022 |
Application Filling date: 25 Mar 2021 Issue date: 30 Sep 2021 |
Grant Utility: Inhibitors of RAF kinases Filling date: 23 Oct 2020 Issue date: 24 Aug 2021 |
Application Filling date: 4 Feb 2021 Issue date: 12 Aug 2021 |
Application Filling date: 11 Nov 2020 Issue date: 6 May 2021 |
| Insider | Compensation |
|---|---|
Mr. Nima Farzan M.B.A. (1976) Pres, Chief Executive Officer & Director | $647,290 |
| Mr. Mark A. Meltz (1973) Chief Operating Officer, Gen. Counsel, Treasurer & Sec. | $496,800 |
-
When is Kinnate Biopharma's next earnings date?
Unfortunately, Kinnate Biopharma's (KNTE) next earnings date is currently unknown.
-
Does Kinnate Biopharma pay dividends?
No, Kinnate Biopharma does not pay dividends.
-
How much money does Kinnate Biopharma make?
Kinnate Biopharma has a market capitalization of 124.99M.
-
What is Kinnate Biopharma's stock symbol?
Kinnate Biopharma Inc. is traded on the NASDAQ under the ticker symbol "KNTE".
-
What is Kinnate Biopharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Kinnate Biopharma?
Shares of Kinnate Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Kinnate Biopharma's key executives?
Kinnate Biopharma's management team includes the following people:
- Mr. Nima Farzan M.B.A. Pres, Chief Executive Officer & Director(age: 49, pay: $647,290)
- Mr. Mark A. Meltz Chief Operating Officer, Gen. Counsel, Treasurer & Sec.(age: 52, pay: $496,800)
-
How many employees does Kinnate Biopharma have?
As Jul 2024, Kinnate Biopharma employs 84 workers.
-
When Kinnate Biopharma went public?
Kinnate Biopharma Inc. is publicly traded company for more then 4 years since IPO on 3 Dec 2020.
-
What is Kinnate Biopharma's official website?
The official website for Kinnate Biopharma is kinnate.com.
-
Where are Kinnate Biopharma's headquarters?
Kinnate Biopharma is headquartered at 103 Montgomery Street, San Francisco, CA.
-
How can i contact Kinnate Biopharma?
Kinnate Biopharma's mailing address is 103 Montgomery Street, San Francisco, CA and company can be reached via phone at 858 299 4699.
Kinnate Biopharma company profile:
Kinnate Biopharma Inc.
kinnate.comExchange:
NASDAQ
Full time employees:
84
Industry:
Biotechnology
Sector:
Healthcare
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
103 Montgomery Street
San Francisco, CA 94129
San Francisco, CA 94129
CIK: 0001797768
ISIN: US49705R1059
CUSIP: 49705R105
